var data={"title":"The dyschromatoses","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">The dyschromatoses</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/the-dyschromatoses/contributors\" class=\"contributor contributor_credentials\">Michihiro Kono, MD, PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/the-dyschromatoses/contributors\" class=\"contributor contributor_credentials\">Jennifer L Hand, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/the-dyschromatoses/contributors\" class=\"contributor contributor_credentials\">Rosamaria Corona, MD, DSc</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/the-dyschromatoses/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Oct 30, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H384754652\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The dyschromatoses are a group of rare, inherited pigmentary disorders characterized by the development during infancy or childhood of numerous, irregular hyperpigmented and hypopigmented macules approximately 5 mm in diameter [<a href=\"https://www.uptodate.com/contents/the-dyschromatoses/abstract/1\" class=\"abstract_t\">1</a>]. Dyschromatosis symmetrica hereditaria (DSH, MIM #127400) and dyschromatosis universalis hereditaria (DUH, DUH1 MIM #127500, DUH2 MIM #612715, DUH3 MIM #615402), which are the two most common dyschromatoses, were first reported and most commonly occur in Japan.</p><p>This topic will discuss the clinical manifestations, diagnosis, and treatment of DSH and DUH. Other congenital and inherited hyperpigmentation disorders and the acquired hyperpigmentation disorders are discussed separately. (See <a href=\"topic.htm?path=acquired-hyperpigmentation-disorders\" class=\"medical medical_review\">&quot;Acquired hyperpigmentation disorders&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H61747388\"><span class=\"h1\">EPIDEMIOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Epidemiologic data on the inherited dyschromatoses are limited. The prevalence of dyschromatosis symmetrica hereditaria (DSH) in Japan is estimated to be approximately 1.5 per 100,000 [<a href=\"https://www.uptodate.com/contents/the-dyschromatoses/abstract/2\" class=\"abstract_t\">2</a>]. The prevalence of dyschromatosis universalis hereditaria (DUH) is probably much lower than DSH prevalence. One study reported that approximately 1.9 and 0.3 per 100,000 dermatology consultations in Japan are related to DSH and DUH, respectively [<a href=\"https://www.uptodate.com/contents/the-dyschromatoses/abstract/3\" class=\"abstract_t\">3</a>].</p><p class=\"headingAnchor\" id=\"H384754658\"><span class=\"h1\">DYSCHROMATOSIS SYMMETRICA HEREDITARIA</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Dyschromatosis symmetrica hereditaria (DSH), also called reticulate acropigmentation of Dohi, is an autosomal dominant disorder characterized by a mixture of hypopigmented and hyperpigmented macules approximately 5 mm in diameter on the dorsa of the hands and feet (<a href=\"image.htm?imageKey=DERM%2F105809\" class=\"graphic graphic_picture graphicRef105809 \">picture 1</a>) and freckle-like macules on the face. First described by Toyama in 1910, DSH has been reported mainly in Japan and China [<a href=\"https://www.uptodate.com/contents/the-dyschromatoses/abstract/4,5\" class=\"abstract_t\">4,5</a>]. However, Korean [<a href=\"https://www.uptodate.com/contents/the-dyschromatoses/abstract/6\" class=\"abstract_t\">6</a>], Taiwanese [<a href=\"https://www.uptodate.com/contents/the-dyschromatoses/abstract/7\" class=\"abstract_t\">7</a>], Thai [<a href=\"https://www.uptodate.com/contents/the-dyschromatoses/abstract/8\" class=\"abstract_t\">8</a>], Indian [<a href=\"https://www.uptodate.com/contents/the-dyschromatoses/abstract/9\" class=\"abstract_t\">9</a>], Turkish [<a href=\"https://www.uptodate.com/contents/the-dyschromatoses/abstract/10\" class=\"abstract_t\">10</a>], European [<a href=\"https://www.uptodate.com/contents/the-dyschromatoses/abstract/11,12\" class=\"abstract_t\">11,12</a>], and Hispanic [<a href=\"https://www.uptodate.com/contents/the-dyschromatoses/abstract/13\" class=\"abstract_t\">13</a>] cases have also been reported.</p><p class=\"headingAnchor\" id=\"H1470423\"><span class=\"h2\">Genetics</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>DSH (MIM#127400) is caused by mutations in the adenosine deaminase acting on RNA1 gene (<em>ADAR1</em>) at 1q21.3<em>, </em>which encodes the RNA editing enzyme [<a href=\"https://www.uptodate.com/contents/the-dyschromatoses/abstract/2\" class=\"abstract_t\">2</a>]. DSH is inherited in an autosomal dominant manner with nearly complete penetrance but variable expressivity. Both familial and sporadic cases have been reported. More than 160 different mutations throughout <em>ADAR1</em> have been described in patients with DSH. These mutations, including nonsense, missense, frameshift, and splice-site mutations, are thought to lead to <em>ADAR1</em> haploinsufficiency. Biallelic mutations in <em>ADAR1</em> cause Aicardi-Gouti&egrave;res syndrome 6 (AGS6, MIM #615010), a severe childhood autoimmune disease characterized by encephalitis and interferonopathy that mimics viral infection [<a href=\"https://www.uptodate.com/contents/the-dyschromatoses/abstract/14\" class=\"abstract_t\">14</a>]. However, DSH is not a feature of AGS. There is a single report of a patient with DSH due to a compound heterozygous <em>ADAR1</em> mutation and associated with severe neurologic symptoms and brain calcification [<a href=\"https://www.uptodate.com/contents/the-dyschromatoses/abstract/15\" class=\"abstract_t\">15</a>].</p><p class=\"headingAnchor\" id=\"H1469335\"><span class=\"h2\">Pathogenesis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Adenosine deaminase acting on RNA1 (ADAR1) is an RNA-editing enzyme that catalyzes the deamination of adenosine to inosine in double-stranded RNA substrates during post-transcription processing [<a href=\"https://www.uptodate.com/contents/the-dyschromatoses/abstract/16\" class=\"abstract_t\">16</a>]. Inosine acts as guanine during translation, resulting in codon alterations or alternative splicing sites that lead to functional changes in proteins [<a href=\"https://www.uptodate.com/contents/the-dyschromatoses/abstract/17\" class=\"abstract_t\">17</a>].</p><p><em>ADAR1</em> has two isoforms of different sizes, regulated by different promoters: constitutively expressed ADAR1-p110 (110 kDa) and interferon-inducible ADAR1-p150 (150 kDa) [<a href=\"https://www.uptodate.com/contents/the-dyschromatoses/abstract/18\" class=\"abstract_t\">18</a>]. Regulated by different promoters, the two variants are thought to be involved in different cellular functions, including stem cell maintenance, protection against stress-induced apoptosis, and innate immune response [<a href=\"https://www.uptodate.com/contents/the-dyschromatoses/abstract/19-22\" class=\"abstract_t\">19-22</a>]. Studies indicate that the interferon-inducible ADAR1-p150 promoter is involved in the modulation of the response to several viral infections, including measles, influenza, hepatitis C, hepatitis D, lymphocytic choriomeningitis, and polyoma virus infection [<a href=\"https://www.uptodate.com/contents/the-dyschromatoses/abstract/23,24\" class=\"abstract_t\">23,24</a>].</p><p>Mutation analysis has shown mutations in the coding region only of the p150 isoform in DSH patients [<a href=\"https://www.uptodate.com/contents/the-dyschromatoses/abstract/25\" class=\"abstract_t\">25</a>]. This finding supports the hypothesis that DSH is caused by the p150 isoform of <em>ADAR1</em>, although the substrate gene edited by ADAR1 in the skin is unknown. Further studies are needed to clarify the mechanisms underlying the degeneration <span class=\"nowrap\">and/or</span> dysfunction of melanocytes in DSH and its localization to the distal extremities and face, despite the ubiquitous expression of <em>ADAR1 </em>[<a href=\"https://www.uptodate.com/contents/the-dyschromatoses/abstract/19,26\" class=\"abstract_t\">19,26</a>].</p><p class=\"headingAnchor\" id=\"H1469243\"><span class=\"h2\">Clinical features</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>DSH is characterized by a mixture of hypopigmented and hyperpigmented macules approximately 5 mm in diameter, distributed predominantly on the dorsal aspect of the hands and feet (<a href=\"image.htm?imageKey=DERM%2F105809\" class=\"graphic graphic_picture graphicRef105809 \">picture 1</a>), but sometimes extending to the dorsal aspect of the extremities (<a href=\"image.htm?imageKey=DERM%2F105810\" class=\"graphic graphic_picture graphicRef105810 \">picture 2</a>). In some patients, freckle-like macules or a mixture of hypopigmented and hyperpigmented macules develop on the face (<a href=\"image.htm?imageKey=DERM%2F105811\" class=\"graphic graphic_picture graphicRef105811 \">picture 3</a>). Palms, soles, and mucosa are uninvolved.</p><p>DSH commonly develops during infancy or early childhood [<a href=\"https://www.uptodate.com/contents/the-dyschromatoses/abstract/27\" class=\"abstract_t\">27</a>]. Lesions first appear before the age of six years in approximately 70 percent of cases [<a href=\"https://www.uptodate.com/contents/the-dyschromatoses/abstract/28\" class=\"abstract_t\">28</a>]. Lesions extend progressively during childhood, become stable before adolescence, and then persist for life [<a href=\"https://www.uptodate.com/contents/the-dyschromatoses/abstract/27,29\" class=\"abstract_t\">27,29</a>]. Skin findings are more pronounced after sun exposure, although patients do not show photosensitivity [<a href=\"https://www.uptodate.com/contents/the-dyschromatoses/abstract/28,30,31\" class=\"abstract_t\">28,30,31</a>].</p><p>Lesions are asymptomatic and do not show telangiectasia, atrophy, or scale. Inter- and intrafamilial phenotypical variation has been reported [<a href=\"https://www.uptodate.com/contents/the-dyschromatoses/abstract/32\" class=\"abstract_t\">32</a>]. It is the author's experience that some parents may have only faint hypopigmented macules on the dorsa of the fingers, whereas their children have widespread macules over the extremities.</p><p>DSH is, in most cases, an isolated disorder. However, there are rare reports of DSH in association with other disorders, including neurologic disorders [<a href=\"https://www.uptodate.com/contents/the-dyschromatoses/abstract/15,29,33\" class=\"abstract_t\">15,29,33</a>], psoriasis [<a href=\"https://www.uptodate.com/contents/the-dyschromatoses/abstract/34\" class=\"abstract_t\">34</a>], acral hypertrophy [<a href=\"https://www.uptodate.com/contents/the-dyschromatoses/abstract/35\" class=\"abstract_t\">35</a>], and depression [<a href=\"https://www.uptodate.com/contents/the-dyschromatoses/abstract/36\" class=\"abstract_t\">36</a>]. Some patients with DSH and neurologic symptoms may in fact have a variant of AGS associated with mutation in <em>ADAR1 </em>[<a href=\"https://www.uptodate.com/contents/the-dyschromatoses/abstract/14,29,33\" class=\"abstract_t\">14,29,33</a>]. (See <a href=\"#H1470423\" class=\"local\">'Genetics'</a> above.)</p><p class=\"headingAnchor\" id=\"H384754671\"><span class=\"h2\">Histopathology</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Histopathologic examination of lesional skin shows little melanin in hypopigmented macules and increased melanin pigmentation in the basal layer of hyperpigmented lesions along with pigmentary incontinence [<a href=\"https://www.uptodate.com/contents/the-dyschromatoses/abstract/7,32\" class=\"abstract_t\">7,32</a>]. In the hypomelanotic areas, as well as in the surrounding normal skin, there is a decreased number of melanocytes; in the hyperchromic areas, melanocytes appear increased in size, with elongated and numerous dendrites, indicating active melanosome transfer to the keratinocytes [<a href=\"https://www.uptodate.com/contents/the-dyschromatoses/abstract/7\" class=\"abstract_t\">7</a>]. Electron microscopy studies have shown abnormalities in melanocytes in the hypomelanotic skin, including a decrease in number, fatty degeneration, vacuolization of cytoplasm, swollen mitochondria, and condensed, irregularly shaped nucleus [<a href=\"https://www.uptodate.com/contents/the-dyschromatoses/abstract/7,32\" class=\"abstract_t\">7,32</a>].</p><p class=\"headingAnchor\" id=\"H384754689\"><span class=\"h1\">DYSCHROMATOSIS UNIVERSALIS HEREDITARIA</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Dyschromatosis universalis hereditaria (DUH) is a rare pigmentary genodermatosis characterized by hypopigmented and hyperpigmented macules involving the entire body surface. First described in 1933 by Ichikawa and Hiraga [<a href=\"https://www.uptodate.com/contents/the-dyschromatoses/abstract/37\" class=\"abstract_t\">37</a>], it occurs predominantly in the Japanese [<a href=\"https://www.uptodate.com/contents/the-dyschromatoses/abstract/38,39\" class=\"abstract_t\">38,39</a>] but has also been reported in other Asian [<a href=\"https://www.uptodate.com/contents/the-dyschromatoses/abstract/40,41\" class=\"abstract_t\">40,41</a>], Middle Eastern [<a href=\"https://www.uptodate.com/contents/the-dyschromatoses/abstract/42,43\" class=\"abstract_t\">42,43</a>], European [<a href=\"https://www.uptodate.com/contents/the-dyschromatoses/abstract/38\" class=\"abstract_t\">38</a>], South American, and African populations [<a href=\"https://www.uptodate.com/contents/the-dyschromatoses/abstract/44-46\" class=\"abstract_t\">44-46</a>].</p><p class=\"headingAnchor\" id=\"H1470200\"><span class=\"h2\">Genetics</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>DUH shows genetic heterogeneity. It is inherited in an autosomal dominant fashion with variable penetrance, but there are reports of autosomal recessive transmission [<a href=\"https://www.uptodate.com/contents/the-dyschromatoses/abstract/42,47\" class=\"abstract_t\">42,47</a>]. Sporadic cases have also been described [<a href=\"https://www.uptodate.com/contents/the-dyschromatoses/abstract/48\" class=\"abstract_t\">48</a>].</p><p>In two Chinese families, the locus for the autosomal dominant form (DUH1, MIM #127500) was mapped at chromosome 6q24-q25.2 [<a href=\"https://www.uptodate.com/contents/the-dyschromatoses/abstract/49\" class=\"abstract_t\">49</a>]. In another pedigree, the locus for the autosomal recessive form, DUH2 (MIM #612715), was mapped at chromosome 12q21-q23 [<a href=\"https://www.uptodate.com/contents/the-dyschromatoses/abstract/47\" class=\"abstract_t\">47</a>]. However, the pathogenic genes of these subtypes have not been identified [<a href=\"https://www.uptodate.com/contents/the-dyschromatoses/abstract/47,49\" class=\"abstract_t\">47,49</a>].</p><p>Subsequent genome-wide linkage analysis studies in two large Chinese kindreds with multiple members affected over five generations indicated that DUH (DUH3, MIM<em> </em>#615402) is caused by mutations in the adenosine triphosphate (ATP)-binding cassette subfamily B, member 6 gene (<em>ABCB6</em>) at 2q35, encoding a transporter protein that regulates de novo porphyrin synthesis [<a href=\"https://www.uptodate.com/contents/the-dyschromatoses/abstract/50,51\" class=\"abstract_t\">50,51</a>].</p><p class=\"headingAnchor\" id=\"H1470262\"><span class=\"h2\">Pathogenesis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>DUH is thought to be caused by a deficiency of melanin synthesis <span class=\"nowrap\">and/or</span> melanosome sorting [<a href=\"https://www.uptodate.com/contents/the-dyschromatoses/abstract/38,52,53\" class=\"abstract_t\">38,52,53</a>]. The <em>ABCB6</em> gene is widely expressed in many tissues. In the skin, the ABCB6 protein is expressed in keratinocytes and melanocytes and has a diffuse cytoplasmic distribution, including the outer mitochondrial membrane, endoplasmic reticulum, Golgi apparatus, plasma membrane, and exosomes [<a href=\"https://www.uptodate.com/contents/the-dyschromatoses/abstract/50\" class=\"abstract_t\">50</a>].</p><p>In a study of mouse melanoma B16 cell line, the wild-type ABCB6 protein was distributed in an endosome-like pattern and was abundant in the dendrites, whereas the ABCB6 protein with the mutations found in DUH was retained in the Golgi body [<a href=\"https://www.uptodate.com/contents/the-dyschromatoses/abstract/50\" class=\"abstract_t\">50</a>]. These preliminary findings suggest that ABCB6 may be involved in the transfer of melanosome to keratinocytes.</p><p class=\"headingAnchor\" id=\"H61746437\"><span class=\"h2\">Histopathology</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Histologic examination of a skin biopsy shows, in DUH, a focal increase or decrease in the melanin content of the basal layer in hyper- and hypopigmented macules, respectively. Pigment incontinence is occasionally observed. An ultrastructural study demonstrated normal numbers of active melanocytes but different amounts of fully melanized melanosomes in hyperpigmented and hypopigmented macules [<a href=\"https://www.uptodate.com/contents/the-dyschromatoses/abstract/38\" class=\"abstract_t\">38</a>].</p><p class=\"headingAnchor\" id=\"H1469621\"><span class=\"h2\">Clinical features</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>DUH usually presents in the first year of life with asymptomatic hyperpigmented and hypopigmented irregular macules similar to those seen in DSH, located mainly on the trunk (<a href=\"image.htm?imageKey=DERM%2F93763\" class=\"graphic graphic_picture graphicRef93763 \">picture 4</a>) but also on the face and extremities [<a href=\"https://www.uptodate.com/contents/the-dyschromatoses/abstract/1\" class=\"abstract_t\">1</a>]. Lesions on the face may resemble ephelides or lentigines. The palms, soles, and mucosal surfaces are usually spared but may be involved [<a href=\"https://www.uptodate.com/contents/the-dyschromatoses/abstract/40,54\" class=\"abstract_t\">40,54</a>].</p><p>DUH usually occurs in isolation. However, there are reports of DUH associated with systemic complications, including short stature, deafness, epilepsy, and erythrocyte, platelet, and tryptophan metabolism abnormalities [<a href=\"https://www.uptodate.com/contents/the-dyschromatoses/abstract/1,40,41,55\" class=\"abstract_t\">1,40,41,55</a>].</p><p class=\"headingAnchor\" id=\"H384754720\"><span class=\"h1\">DIAGNOSIS AND DIFFERENTIAL DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The diagnosis of inherited dyschromatosis is usually clinical. Histology is nonspecific and shows focal increase or decrease in melanin content of the basal layer in the hyperpigmented and hypopigmented macules, respectively.</p><p>Although the individual macular lesions of dyschromatosis symmetrica hereditaria (DSH) and dyschromatosis universalis hereditaria (DUH) are indistinguishable on typical cases, differentiating DSH from DUH is usually not difficult based upon clinical findings, including lesion distribution and time of onset. In DSH, lesions manifest during childhood and are typically limited to the distal extremities, whereas, in DUH, lesions appear in the first year of life on the trunk and then extend to the entire body surface.</p><p>Genetic testing is not routinely performed; however, it may be helpful in difficult cases to differentiate DSH and DUH from each other and from other inherited disorders of pigmentation. Inherited and acquired pigmentary disorders that may be confused with DSH or DUH include:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Reticulate acropigmentation of Kitamura</strong> &ndash; Reticulate acropigmentation of Kitamura (RAK, MIM #615537) is a rare genodermatosis caused by mutations in the <em>ADAM10</em> gene, encoding A disintegrin and metalloproteinase domain-containing protein 10 [<a href=\"https://www.uptodate.com/contents/the-dyschromatoses/abstract/56\" class=\"abstract_t\">56</a>]. RAK is characterized by dot-like or reticulate, slightly depressed, sharply demarcated, hyperpigmented macules affecting the dorsa of the hands (<a href=\"image.htm?imageKey=DERM%2F105812\" class=\"graphic graphic_picture graphicRef105812 \">picture 5</a>) and feet and palmoplantar pits [<a href=\"https://www.uptodate.com/contents/the-dyschromatoses/abstract/57\" class=\"abstract_t\">57</a>]. In contrast to DSH, hypopigmented macules are absent in RAK. (See <a href=\"topic.htm?path=congenital-and-inherited-hyperpigmentation-disorders#H2805880534\" class=\"medical medical_review\">&quot;Congenital and inherited hyperpigmentation disorders&quot;, section on 'Reticulate acropigmentation of Kitamura'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Xeroderma pigmentosum</strong> &ndash; Xeroderma pigmentosum (XP) is a rare autosomal recessive disease caused by mutations in genes involved in nucleotide excision repair of carcinogen adducts induced by ultraviolet (UV) irradiation [<a href=\"https://www.uptodate.com/contents/the-dyschromatoses/abstract/58\" class=\"abstract_t\">58</a>]. XP is characterized by extreme sensitivity of the skin to sunlight, abnormal pigmentation, xerosis, telangiectasia, atrophy, and a high tendency to develop skin cancers at a very early age. Mild cases of XP or the early stage of XP in a child may be sometimes difficult to differentiate from DSH [<a href=\"https://www.uptodate.com/contents/the-dyschromatoses/abstract/31\" class=\"abstract_t\">31</a>]. Photosensitivity tests, cellular hypersensitivity to UV radiation, complementation studies and chromosomal breakage studies using the patient's fibroblasts, and genetic analyses can be performed for definite diagnosis [<a href=\"https://www.uptodate.com/contents/the-dyschromatoses/abstract/31\" class=\"abstract_t\">31</a>]. (See <a href=\"topic.htm?path=the-genodermatoses#H523750964\" class=\"medical medical_review\">&quot;The genodermatoses&quot;, section on 'Xeroderma pigmentosum'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Amyloidosis cutis dyschromica </strong>&ndash; Amyloidosis cutis dyschromica is an exceedingly rare type of primary cutaneous amyloidosis characterized by reticular hyperpigmentation with hypopigmented macules distributed over nearly all of the body (<a href=\"image.htm?imageKey=DERM%2F94996\" class=\"graphic graphic_picture graphicRef94996 \">picture 6</a>). Histologic examination of a skin biopsy shows hyperkeratosis, necrotic keratinocytes in the basal layer, and melanophages as well as amorphous eosinophilic material (amyloid) deposits in the upper dermis. (See <a href=\"topic.htm?path=acquired-hyperpigmentation-disorders#H312764203\" class=\"medical medical_review\">&quot;Acquired hyperpigmentation disorders&quot;, section on 'Primary cutaneous amyloidosis'</a>.)</p><p/><p>Exposure to chemicals that are toxic to melanocytes, such as diphenylcyclopropenone and monobenzyl ether of <a href=\"topic.htm?path=hydroquinone-drug-information\" class=\"drug drug_general\">hydroquinone</a>, may cause patchy depigmentation that may mimic the dyschromatoses [<a href=\"https://www.uptodate.com/contents/the-dyschromatoses/abstract/59\" class=\"abstract_t\">59</a>]. History of exposure to these agents usually clarifies the diagnosis. Histologic examination of a skin biopsy shows absence of melanocytes in the hypopigmented areas.</p><p class=\"headingAnchor\" id=\"H384754726\"><span class=\"h1\">TREATMENT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>There are no effective treatments for the hereditary dyschromatoses. Because tanning emphasizes the contrast between hyperpigmented and hypopigmented spots, patients with dyschromatosis should adopt photoprotection measures, including sun avoidance and use of protective clothing and broad-spectrum sunscreens with a sun protection factor (SPF) of at least 30.</p><p>There is a single case report of treatment of DSH lesions using miniature punch grafting followed by excimer light therapy [<a href=\"https://www.uptodate.com/contents/the-dyschromatoses/abstract/60\" class=\"abstract_t\">60</a>]. The Q-switched alexandrite laser has been successfully used to remove facial and labial lentigines in a single patient with DUH [<a href=\"https://www.uptodate.com/contents/the-dyschromatoses/abstract/61\" class=\"abstract_t\">61</a>].</p><p class=\"headingAnchor\" id=\"H1470585\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The dyschromatoses are a group of rare inherited pigmentary disorders mainly reported in Japan and China and characterized by the presence of numerous irregular hyperpigmented and hypopigmented macules approximately 5 mm in diameter. (See <a href=\"#H384754652\" class=\"local\">'Introduction'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Dyschromatosis symmetrica hereditaria (DSH), also called reticulate acropigmentation of Dohi, is an autosomal dominant disorder caused by mutations in <em>ADAR1</em> gene, encoding the RNA editing enzyme<em> </em>adenosine deaminases acting on RNA1 (ADAR1). DSH develops during infancy or early childhood and is characterized by a mixture of hypopigmented and hyperpigmented macules approximately 5 mm in diameter on the dorsa of the hands and feet and freckle-like macules on the face (<a href=\"image.htm?imageKey=DERM%2F94173%7EDERM%2F94994\" class=\"graphic graphic_picture graphicRef94173 graphicRef94994 \">picture 7A-B</a>). (See <a href=\"#H384754658\" class=\"local\">'Dyschromatosis symmetrica hereditaria'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Dyschromatosis universalis hereditaria (DUH) is a rare pigmentary genodermatosis characterized by hypopigmented and hyperpigmented macules, which is the same as the lesion of DSH, involving the entire body surface (<a href=\"image.htm?imageKey=DERM%2F93763\" class=\"graphic graphic_picture graphicRef93763 \">picture 4</a>). DUH is inherited in an autosomal dominant or recessive manner and shows genetic heterogeneity. DUH has been reported in association with short stature, deafness, epilepsy, and erythrocyte, platelet, and tryptophan metabolism abnormalities. (See <a href=\"#H384754689\" class=\"local\">'Dyschromatosis universalis hereditaria'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The diagnosis of inherited dyschromatosis is usually clinical. Histology is nonspecific and shows focal increase or decrease in melanin content of the basal layer. Genetic testing is not routinely performed; however, it may be helpful in difficult cases to differentiate DSH and DUH from each other and from other inherited or acquired disorders presenting with dyspigmentation, such as reticulate acropigmentation of Kitamura (RAK), xeroderma pigmentosum (XP), and amyloidosis cutis dyschromica. (See <a href=\"#H384754720\" class=\"local\">'Diagnosis and differential diagnosis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>There are no effective treatments for the inherited dyschromatoses. Photoprotection measures, including sun avoidance and use of protective clothing and broad-spectrum sunscreens with a sun protection factor (SPF) of at least 30 may be helpful to avoid contrast enhancement between hyperpigmented and hypopigmented macules. (See <a href=\"#H384754726\" class=\"local\">'Treatment'</a> above.)</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/the-dyschromatoses/abstract/1\" class=\"nounderline abstract_t\">Urabe K, Hori Y. Dyschromatosis. Semin Cutan Med Surg 1997; 16:81.</a></li><li><a href=\"https://www.uptodate.com/contents/the-dyschromatoses/abstract/2\" class=\"nounderline abstract_t\">Miyamura Y, Suzuki T, Kono M, et al. Mutations of the RNA-specific adenosine deaminase gene (DSRAD) are involved in dyschromatosis symmetrica hereditaria. Am J Hum Genet 2003; 73:693.</a></li><li><a href=\"https://www.uptodate.com/contents/the-dyschromatoses/abstract/3\" class=\"nounderline abstract_t\">Fukai K, Oiso N, Kawaguchi M, et al. Guidelines for the diagnosis and treatment of oculo-cutaneous albinism in Japan (in Japanese). Jpn J Dermatol 2014; 124:1897.</a></li><li><a href=\"https://www.uptodate.com/contents/the-dyschromatoses/abstract/4\" class=\"nounderline abstract_t\">Toyama I. An unknown disorder of hyperpigmentation (in Japanese). Jpn J Dermatol Urol 1910; 10:644.</a></li><li><a href=\"https://www.uptodate.com/contents/the-dyschromatoses/abstract/5\" class=\"nounderline abstract_t\">Toyama I. Dyschromatosis symmetrica hereditaria (in Japanese). Jpn J Dermatol Urol 1929; 29:95.</a></li><li><a href=\"https://www.uptodate.com/contents/the-dyschromatoses/abstract/6\" class=\"nounderline abstract_t\">Kim NI, Park SA, Youn JI. Dyschromatosis symmetrica hereditaria affecting two families. Korean J Dermatol 1980; 18:585.</a></li><li><a href=\"https://www.uptodate.com/contents/the-dyschromatoses/abstract/7\" class=\"nounderline abstract_t\">Sheu HM, Yu HS. Dyschromatosis symmetrica hereditaria--a histochemical and ultrastructural study. Taiwan Yi Xue Hui Za Zhi 1985; 84:238.</a></li><li><a href=\"https://www.uptodate.com/contents/the-dyschromatoses/abstract/8\" class=\"nounderline abstract_t\">Kantaputra PN, Chinadet W, Ohazama A, Kono M. Dyschromatosis symmetrica hereditaria with long hair on the forearms, hypo/hyperpigmented hair, and dental anomalies: report of a novel ADAR1 mutation. Am J Med Genet A 2012; 158A:2258.</a></li><li><a href=\"https://www.uptodate.com/contents/the-dyschromatoses/abstract/9\" class=\"nounderline abstract_t\">Dhar S, Malakar S. Acropigmentation of Dohi in a 12-year-old boy. Pediatr Dermatol 1998; 15:242.</a></li><li><a href=\"https://www.uptodate.com/contents/the-dyschromatoses/abstract/10\" class=\"nounderline abstract_t\">Bilen N, Akt&uuml;rk A&#350;, Kawaguchi M, et al. Dyschromatosis symmetrica hereditaria: a case report from Turkey, a new association and a novel gene mutation. J Dermatol 2012; 39:857.</a></li><li><a href=\"https://www.uptodate.com/contents/the-dyschromatoses/abstract/11\" class=\"nounderline abstract_t\">Patrizi A, Manneschi V, Pini A, et al. Dyschromatosis symmetrica hereditaria associated with idiopathic torsion dystonia. A case report. Acta Derm Venereol 1994; 74:135.</a></li><li><a href=\"https://www.uptodate.com/contents/the-dyschromatoses/abstract/12\" class=\"nounderline abstract_t\">Ostlere LS, Ratnavel RC, Lawlor F, et al. Reticulate acropigmentation of Dohi. Clin Exp Dermatol 1995; 20:477.</a></li><li><a href=\"https://www.uptodate.com/contents/the-dyschromatoses/abstract/13\" class=\"nounderline abstract_t\">Kono M, Akiyama M, Suganuma M, et al. Dyschromatosis symmetrica hereditaria by ADAR1 mutations and viral encephalitis: a hidden link? Int J Dermatol 2013; 52:1582.</a></li><li><a href=\"https://www.uptodate.com/contents/the-dyschromatoses/abstract/14\" class=\"nounderline abstract_t\">Rice GI, Kasher PR, Forte GM, et al. Mutations in ADAR1 cause Aicardi-Gouti&egrave;res syndrome associated with a type I interferon signature. Nat Genet 2012; 44:1243.</a></li><li><a href=\"https://www.uptodate.com/contents/the-dyschromatoses/abstract/15\" class=\"nounderline abstract_t\">Kono M, Matsumoto F, Suzuki Y, et al. Dyschromatosis Symmetrica Hereditaria and Aicardi-Gouti&egrave;res Syndrome 6 Are Phenotypic Variants Caused by ADAR1 Mutations. J Invest Dermatol 2016; 136:875.</a></li><li><a href=\"https://www.uptodate.com/contents/the-dyschromatoses/abstract/16\" class=\"nounderline abstract_t\">Bass BL, Weintraub H. An unwinding activity that covalently modifies its double-stranded RNA substrate. Cell 1988; 55:1089.</a></li><li><a href=\"https://www.uptodate.com/contents/the-dyschromatoses/abstract/17\" class=\"nounderline abstract_t\">Rueter SM, Dawson TR, Emeson RB. Regulation of alternative splicing by RNA editing. Nature 1999; 399:75.</a></li><li><a href=\"https://www.uptodate.com/contents/the-dyschromatoses/abstract/18\" class=\"nounderline abstract_t\">Patterson JB, Samuel CE. Expression and regulation by interferon of a double-stranded-RNA-specific adenosine deaminase from human cells: evidence for two forms of the deaminase. Mol Cell Biol 1995; 15:5376.</a></li><li><a href=\"https://www.uptodate.com/contents/the-dyschromatoses/abstract/19\" class=\"nounderline abstract_t\">Wang Q, Miyakoda M, Yang W, et al. Stress-induced apoptosis associated with null mutation of ADAR1 RNA editing deaminase gene. J Biol Chem 2004; 279:4952.</a></li><li><a href=\"https://www.uptodate.com/contents/the-dyschromatoses/abstract/20\" class=\"nounderline abstract_t\">Qiu W, Wang X, Buchanan M, et al. ADAR1 is essential for intestinal homeostasis and stem cell maintenance. Cell Death Dis 2013; 4:e599.</a></li><li><a href=\"https://www.uptodate.com/contents/the-dyschromatoses/abstract/21\" class=\"nounderline abstract_t\">Hartner JC, Walkley CR, Lu J, Orkin SH. ADAR1 is essential for the maintenance of hematopoiesis and suppression of interferon signaling. Nat Immunol 2009; 10:109.</a></li><li><a href=\"https://www.uptodate.com/contents/the-dyschromatoses/abstract/22\" class=\"nounderline abstract_t\">George CX, John L, Samuel CE. An RNA editor, adenosine deaminase acting on double-stranded RNA (ADAR1). J Interferon Cytokine Res 2014; 34:437.</a></li><li><a href=\"https://www.uptodate.com/contents/the-dyschromatoses/abstract/23\" class=\"nounderline abstract_t\">Patterson JB, Thomis DC, Hans SL, Samuel CE. Mechanism of interferon action: double-stranded RNA-specific adenosine deaminase from human cells is inducible by alpha and gamma interferons. Virology 1995; 210:508.</a></li><li><a href=\"https://www.uptodate.com/contents/the-dyschromatoses/abstract/24\" class=\"nounderline abstract_t\">Samuel CE. Adenosine deaminases acting on RNA (ADARs) are both antiviral and proviral. Virology 2011; 411:180.</a></li><li><a href=\"https://www.uptodate.com/contents/the-dyschromatoses/abstract/25\" class=\"nounderline abstract_t\">Suzuki N, Suzuki T, Inagaki K, et al. Ten novel mutations of the ADAR1 gene in Japanese patients with dyschromatosis symmetrica hereditaria. J Invest Dermatol 2007; 127:309.</a></li><li><a href=\"https://www.uptodate.com/contents/the-dyschromatoses/abstract/26\" class=\"nounderline abstract_t\">Samuel CE. Antiviral actions of interferons. Clin Microbiol Rev 2001; 14:778.</a></li><li><a href=\"https://www.uptodate.com/contents/the-dyschromatoses/abstract/27\" class=\"nounderline abstract_t\">Tomita Y, Suzuki T. Genetics of pigmentary disorders. Am J Med Genet C Semin Med Genet 2004; 131C:75.</a></li><li><a href=\"https://www.uptodate.com/contents/the-dyschromatoses/abstract/28\" class=\"nounderline abstract_t\">Oyama M, Shimizu H, Ohata Y, et al. Dyschromatosis symmetrica hereditaria (reticulate acropigmentation of Dohi): report of a Japanese family with the condition and a literature review of 185 cases. Br J Dermatol 1999; 140:491.</a></li><li><a href=\"https://www.uptodate.com/contents/the-dyschromatoses/abstract/29\" class=\"nounderline abstract_t\">Kondo T, Suzuki T, Ito S, et al. Dyschromatosis symmetrica hereditaria associated with neurological disorders. J Dermatol 2008; 35:662.</a></li><li><a href=\"https://www.uptodate.com/contents/the-dyschromatoses/abstract/30\" class=\"nounderline abstract_t\">Hou Y, Chen J, Gao M, et al. Five novel mutations of RNA-specific adenosine deaminase gene with dyschromatosis symmetrica hereditaria. Acta Derm Venereol 2007; 87:18.</a></li><li><a href=\"https://www.uptodate.com/contents/the-dyschromatoses/abstract/31\" class=\"nounderline abstract_t\">Nishigori C, Miyachi Y, Takebe H, Imamura S. A case of xeroderma pigmentosum with clinical appearance of dyschromatosis symmetrica hereditaria. Pediatr Dermatol 1986; 3:410.</a></li><li><a href=\"https://www.uptodate.com/contents/the-dyschromatoses/abstract/32\" class=\"nounderline abstract_t\">Kondo T, Suzuki T, Mitsuhashi Y, et al. Six novel mutations of the ADAR1 gene in patients with dyschromatosis symmetrica hereditaria: histological observation and comparison of genotypes and clinical phenotypes. J Dermatol 2008; 35:395.</a></li><li><a href=\"https://www.uptodate.com/contents/the-dyschromatoses/abstract/33\" class=\"nounderline abstract_t\">Tojo K, Sekijima Y, Suzuki T, et al. Dystonia, mental deterioration, and dyschromatosis symmetrica hereditaria in a family with ADAR1 mutation. Mov Disord 2006; 21:1510.</a></li><li><a href=\"https://www.uptodate.com/contents/the-dyschromatoses/abstract/34\" class=\"nounderline abstract_t\">Shi BJ, Xue M, Liu Y, et al. First report of the coexistence of dyschromatosis symmetrica hereditaria and psoriasis: one novel TCT to A mutation in the double-RNA-specific adenosine deaminase gene. J Eur Acad Dermatol Venereol 2012; 26:657.</a></li><li><a href=\"https://www.uptodate.com/contents/the-dyschromatoses/abstract/35\" class=\"nounderline abstract_t\">Murata T, Yagi Y, Tanioka M, et al. Dyschromatosis symmetrica hereditaria with acral hypertrophy. Eur J Dermatol 2011; 21:649.</a></li><li><a href=\"https://www.uptodate.com/contents/the-dyschromatoses/abstract/36\" class=\"nounderline abstract_t\">Luo S, Zheng Y, Ni H, et al. Novel clinical and molecular findings in Chinese families with dyschromatosis symmetrica hereditaria. J Dermatol 2012; 39:556.</a></li><li><a href=\"https://www.uptodate.com/contents/the-dyschromatoses/abstract/37\" class=\"nounderline abstract_t\">Ichikawa T, Hiraga Y. A previously undescribed anomaly of pigmentation dyschromatosis universalis hereditaria. Jpn J Dermatol Urol 1933; 34:360.</a></li><li><a href=\"https://www.uptodate.com/contents/the-dyschromatoses/abstract/38\" class=\"nounderline abstract_t\">Nuber UA, Tinschert S, Mundlos S, Hauber I. Dyschromatosis universalis hereditaria: familial case and ultrastructural skin investigation. Am J Med Genet A 2004; 125A:261.</a></li><li><a href=\"https://www.uptodate.com/contents/the-dyschromatoses/abstract/39\" class=\"nounderline abstract_t\">SUENAGA M. Genetical studies on skin diseases. VII. Dyschromatosis universalis hereditaria in 5 generations. Tohoku J Exp Med 1952; 55:373.</a></li><li><a href=\"https://www.uptodate.com/contents/the-dyschromatoses/abstract/40\" class=\"nounderline abstract_t\">Udayashankar C, Nath AK. Dyschromatosis universalis hereditaria: a case report. Dermatol Online J 2011; 17:2.</a></li><li><a href=\"https://www.uptodate.com/contents/the-dyschromatoses/abstract/41\" class=\"nounderline abstract_t\">Sethuraman G, Srinivas CR, D'Souza M, et al. Dyschromatosis universalis hereditaria. Clin Exp Dermatol 2002; 27:477.</a></li><li><a href=\"https://www.uptodate.com/contents/the-dyschromatoses/abstract/42\" class=\"nounderline abstract_t\">Bukhari IA, El-Harith EA, Stuhrmann M. Dyschromatosis universalis hereditaria as an autosomal recessive disease in five members of one family. J Eur Acad Dermatol Venereol 2006; 20:628.</a></li><li><a href=\"https://www.uptodate.com/contents/the-dyschromatoses/abstract/43\" class=\"nounderline abstract_t\">Al Hawsawi K, Al Aboud K, Ramesh V, Al Aboud D. Dyschromatosis universalis hereditaria: report of a case and review of the literature. Pediatr Dermatol 2002; 19:523.</a></li><li><a href=\"https://www.uptodate.com/contents/the-dyschromatoses/abstract/44\" class=\"nounderline abstract_t\">Yusuf SM, Mijinyawa MS, Maiyaki MB, Mohammed AZ. Dyschromatosis universalis hereditaria in a young Nigerian female. Int J Dermatol 2009; 48:749.</a></li><li><a href=\"https://www.uptodate.com/contents/the-dyschromatoses/abstract/45\" class=\"nounderline abstract_t\">Kenani N, Ghariani N, Denguezli M, et al. Dyschromatosis universalis hereditaria: two cases. Dermatol Online J 2008; :16.</a></li><li><a href=\"https://www.uptodate.com/contents/the-dyschromatoses/abstract/46\" class=\"nounderline abstract_t\">Reddy SG, Worobec SM. Dyschromatosis universalis hereditaria in an African American male. Dermatol Online J 2011; 17:3.</a></li><li><a href=\"https://www.uptodate.com/contents/the-dyschromatoses/abstract/47\" class=\"nounderline abstract_t\">Stuhrmann M, Hennies HC, Bukhari IA, et al. Dyschromatosis universalis hereditaria: evidence for autosomal recessive inheritance and identification of a new locus on chromosome 12q21-q23. Clin Genet 2008; 73:566.</a></li><li><a href=\"https://www.uptodate.com/contents/the-dyschromatoses/abstract/48\" class=\"nounderline abstract_t\">An JM, Ko BJ, Cho MK, Whang KU. A Case of Sporadic Dyschromatosis Universalis Hereditaria. Ann Dermatol 2015; 27:467.</a></li><li><a href=\"https://www.uptodate.com/contents/the-dyschromatoses/abstract/49\" class=\"nounderline abstract_t\">Xing QH, Wang MT, Chen XD, et al. A gene locus responsible for dyschromatosis symmetrica hereditaria (DSH) maps to chromosome 6q24.2-q25.2. Am J Hum Genet 2003; 73:377.</a></li><li><a href=\"https://www.uptodate.com/contents/the-dyschromatoses/abstract/50\" class=\"nounderline abstract_t\">Zhang C, Li D, Zhang J, et al. Mutations in ABCB6 cause dyschromatosis universalis hereditaria. J Invest Dermatol 2013; 133:2221.</a></li><li><a href=\"https://www.uptodate.com/contents/the-dyschromatoses/abstract/51\" class=\"nounderline abstract_t\">Liu H, Li Y, Hung KK, et al. Genome-wide linkage, exome sequencing and functional analyses identify ABCB6 as the pathogenic gene of dyschromatosis universalis hereditaria. PLoS One 2014; 9:e87250.</a></li><li><a href=\"https://www.uptodate.com/contents/the-dyschromatoses/abstract/52\" class=\"nounderline abstract_t\">Wang G, Li CY, Gao TW, Liu YF. Dyschromatosis universalis hereditaria: two cases in a Chinese family. Clin Exp Dermatol 2005; 30:494.</a></li><li><a href=\"https://www.uptodate.com/contents/the-dyschromatoses/abstract/53\" class=\"nounderline abstract_t\">Kim NS, Im S, Kim SC. Dyschromatosis universalis hereditaria: an electron microscopic examination. J Dermatol 1997; 24:161.</a></li><li><a href=\"https://www.uptodate.com/contents/the-dyschromatoses/abstract/54\" class=\"nounderline abstract_t\">Naveen KN, Dinesh US. Dyschromatosis universalis hereditaria with involvement of palms. Indian Dermatol Online J 2014; 5:296.</a></li><li><a href=\"https://www.uptodate.com/contents/the-dyschromatoses/abstract/55\" class=\"nounderline abstract_t\">Shono S, Toda K. Universal dyschromatosis associated with photosensitivity and neurosensory hearing defect. Arch Dermatol 1990; 126:1659.</a></li><li><a href=\"https://www.uptodate.com/contents/the-dyschromatoses/abstract/56\" class=\"nounderline abstract_t\">Kono M, Sugiura K, Suganuma M, et al. Whole-exome sequencing identifies ADAM10 mutations as a cause of reticulate acropigmentation of Kitamura, a clinical entity distinct from Dowling-Degos disease. Hum Mol Genet 2013; 22:3524.</a></li><li><a href=\"https://www.uptodate.com/contents/the-dyschromatoses/abstract/57\" class=\"nounderline abstract_t\">Kono M, Suganuma M, Takama H, et al. Dowling-Degos disease with mutations in POFUT1 is clinicopathologically distinct from reticulate acropigmentation of Kitamura. Br J Dermatol 2015; 173:584.</a></li><li><a href=\"https://www.uptodate.com/contents/the-dyschromatoses/abstract/58\" class=\"nounderline abstract_t\">DiGiovanna JJ, Kraemer KH. Shining a light on xeroderma pigmentosum. J Invest Dermatol 2012; 132:785.</a></li><li><a href=\"https://www.uptodate.com/contents/the-dyschromatoses/abstract/59\" class=\"nounderline abstract_t\">Vachiramon V, Thadanipon K, Rattanakaemakorn P. Adult-onset dyschromatoses. Clin Exp Dermatol 2012; 37:97.</a></li><li><a href=\"https://www.uptodate.com/contents/the-dyschromatoses/abstract/60\" class=\"nounderline abstract_t\">Kawakami T, Otaguchi R, Kyoya M, et al. Patient with dyschromatosis symmetrica hereditaria treated with miniature punch grafting, followed by excimer light therapy. J Dermatol 2013; 40:771.</a></li><li><a href=\"https://www.uptodate.com/contents/the-dyschromatoses/abstract/61\" class=\"nounderline abstract_t\">Nogita T, Mitsuhashi Y, Takeo C, Tsuboi R. Removal of facial and labial lentigines in dyschromatosis universalis hereditaria with a Q-switched alexandrite laser. J Am Acad Dermatol 2011; 65:e61.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 15525 Version 8.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H1470585\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H384754652\" id=\"outline-link-H384754652\">INTRODUCTION</a></li><li><a href=\"#H61747388\" id=\"outline-link-H61747388\">EPIDEMIOLOGY</a></li><li><a href=\"#H384754658\" id=\"outline-link-H384754658\">DYSCHROMATOSIS SYMMETRICA HEREDITARIA</a><ul><li><a href=\"#H1470423\" id=\"outline-link-H1470423\">Genetics</a></li><li><a href=\"#H1469335\" id=\"outline-link-H1469335\">Pathogenesis</a></li><li><a href=\"#H1469243\" id=\"outline-link-H1469243\">Clinical features</a></li><li><a href=\"#H384754671\" id=\"outline-link-H384754671\">Histopathology</a></li></ul></li><li><a href=\"#H384754689\" id=\"outline-link-H384754689\">DYSCHROMATOSIS UNIVERSALIS HEREDITARIA</a><ul><li><a href=\"#H1470200\" id=\"outline-link-H1470200\">Genetics</a></li><li><a href=\"#H1470262\" id=\"outline-link-H1470262\">Pathogenesis</a></li><li><a href=\"#H61746437\" id=\"outline-link-H61746437\">Histopathology</a></li><li><a href=\"#H1469621\" id=\"outline-link-H1469621\">Clinical features</a></li></ul></li><li><a href=\"#H384754720\" id=\"outline-link-H384754720\">DIAGNOSIS AND DIFFERENTIAL DIAGNOSIS</a></li><li><a href=\"#H384754726\" id=\"outline-link-H384754726\">TREATMENT</a></li><li><a href=\"#H1470585\" id=\"outline-link-H1470585\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DERM/15525|PIC\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"PICTURES\">PICTURES</a></div><ul><li><a href=\"image.htm?imageKey=DERM/105809\" class=\"graphic graphic_picture\">- Dyschromatosis symmetric ahereditaria hands-foot</a></li><li><a href=\"image.htm?imageKey=DERM/105810\" class=\"graphic graphic_picture\">- Dyschromatosis symmetrica hereditaria knees</a></li><li><a href=\"image.htm?imageKey=DERM/105811\" class=\"graphic graphic_picture\">- Dyschromatosis symmetrica hereditaria face</a></li><li><a href=\"image.htm?imageKey=DERM/93763\" class=\"graphic graphic_picture\">- Dyschromatosis universalis hereditaria</a></li><li><a href=\"image.htm?imageKey=DERM/105812\" class=\"graphic graphic_picture\">- Reticulate acropigmentation of Kitamura</a></li><li><a href=\"image.htm?imageKey=DERM/94996\" class=\"graphic graphic_picture\">- Amyloidosis cutis dyschromica</a></li><li><a href=\"image.htm?imageKey=DERM/94173\" class=\"graphic graphic_picture\">- Dyschromatosis symmetrica hereditaria</a></li><li><a href=\"image.htm?imageKey=DERM/94994\" class=\"graphic graphic_picture\">- Dyschromatosis symmetrica hereditaria 2</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=acquired-hyperpigmentation-disorders\" class=\"medical medical_review\">Acquired hyperpigmentation disorders</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=congenital-and-inherited-hyperpigmentation-disorders\" class=\"medical medical_review\">Congenital and inherited hyperpigmentation disorders</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=the-genodermatoses\" class=\"medical medical_review\">The genodermatoses</a></li></ul></div></div>","javascript":null}